Antheia Overview

  • Founded

  • 2013

Founded
  • Status

  • Private

  • Employees

  • 48

Employees
  • Latest Deal Type

  • Later Stage VC

  • Latest Deal Amount

  • $40M

  • Investors

  • 15

Antheia General Information

Description

Operator of a biotechnology company intended to develop plant-inspired medicines. The company's cost-competitive, plant-based medicines are made using synthetic biology, informatics, and fermentation technology to harness beneficial molecules from plants to create active pharmaceutical ingredients, enabling healthcare organizations to provide patients with natural and healthier medication.

Contact Information

Website
www.antheia.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 1430 O'Brien Drive
  • Suite A
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Antheia Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antheia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 31-Aug-2022 $40M 00000 Completed Generating Revenue
11. Later Stage VC (Series B) 30-Jun-2021 0000 000.00 00000 Completed Product Development
10. Debt - PPP 13-Apr-2020 00000 000.00 Completed Product Development
9. Later Stage VC (Series A) 01-Jan-2020 000.00 Completed Product Development
8. Debt - General 31-Dec-2019 00.000 000.00 Completed Product Development
7. Debt - General 01-Dec-2018 00.000 000.00 Completed Product Development
6. Later Stage VC (Series B) 04-Sep-2018 00.00 000.00 00000 Completed Product Development
5. Grant 01-Jan-2018 00000 00.00 Completed Startup
4. Early Stage VC (Series A) 26-May-2017 $6.22M $8.2M 00000 Completed Startup
3. Grant 01-Jan-2017 $900K $1.97M Completed Startup
To view Antheia’s complete valuation and funding history, request access »

Antheia Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B-3 0,000,000 00.000000 00.0 00.00 00.00 00 00.00 00.000
Series B-2 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series B-1 000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Series A 6,880,436 $0.000100 $0.71 $8.89 $8.89 1x $8.6 23.35%
Seed 2,237,536 $0.000100 $0.09 $1.12 $1.12 1x $1.12 7.35%
To view Antheia’s complete cap table history, request access »

Antheia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop plant-inspired medicines. The company's cost-competitive, plant-
Drug Discovery
Menlo Park, CA
48 As of 2022
00000
0000000000 0 00000

000000

p ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate v
0000000000000
Boston, MA
0000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Antheia Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000 00000000 Formerly VC-backed Boston, MA 0000 00.000 000000000 00.000
You’re viewing 1 of 1 competitors. Get the full list »

Antheia Patents

  • 89

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 7

    Granted

  • 2

    Pending

  • 000

    Expiring in next 12 mo

Antheia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3134602-A1 Methods of improving production of morphinan alkaloids and derivatives Pending 26-Mar-2019 0000000000
EP-3947633-A4 Methods of improving production of morphinan alkaloids and derivatives Pending 26-Mar-2019 000000000 0
EP-3947633-A1 Methods of improving production of morphinan alkaloids and derivatives Pending 26-Mar-2019 0000000000
US-20220162656-A1 Methods of improving production of morphinan alkaloids and derivatives Pending 26-Mar-2019 0000000000
AU-2019216948-A1 Methods of producing morphinan alkaloids and derivatives Pending 08-Feb-2018 C12N15/52
To view Antheia’s complete patent history, request access »

Antheia Executive Team (10)

Name Title Board Seat Contact Info
Christina Smolke Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Zack McGahey Chief Operating Officer
Heidi Pucel Chief People Officer
Kristy Hawkins Ph.D Co-Founder, Chief Scientific Officer, Scientist and Board Member
Antonij Tjahjadi Controller
You’re viewing 5 of 10 executive team members. Get the full list »

Antheia Board Members (5)

Name Representing Role Since
Christina Smolke Ph.D Antheia Co-Founder, Chief Executive Officer, President & Board Member 000 0000
John Nicols Self Chairman 000 0000
Kristy Hawkins Ph.D Antheia Co-Founder, Chief Scientific Officer, Scientist and Board Member 000 0000
Patrick Yang Ph.D Self Board Member 000 0000
Ram Shriram Self Board Member 000 0000
To view Antheia’s complete board members history, request access »

Antheia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antheia Investors (15)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Hillspire Family Office Minority 000 0000 000000 0
Irregular Expressions Venture Capital Minority 000 0000 000000 0
Viking Global Investors Hedge Fund Minority 000 0000 000000 0
Civilization Ventures Venture Capital Minority 000 0000 000000 0
Western Technology Investment Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 15 investors. Get the full list »

Ready to get started?

Request a free trial